|
[1]
|
Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase®)
Antibiotics,
2023
DOI:10.3390/antibiotics12050811
|
|
|
|
|
[2]
|
Adverse drug reactions and associated factors in multidrug-resistant tuberculosis: A retrospective review of patient medical records at Mbarara Regional Referral Hospital, Uganda
SAGE Open Medicine,
2023
DOI:10.1177/20503121231171350
|
|
|
|
|
[3]
|
Challenges in the management of depressive disorders comorbid with tuberculosis and type 2 diabetes
Current Opinion in Psychiatry,
2023
DOI:10.1097/YCO.0000000000000885
|
|
|
|
|
[4]
|
Challenges in the management of depressive disorders comorbid with tuberculosis and type 2 diabetes
Current Opinion in Psychiatry,
2023
DOI:10.1097/YCO.0000000000000885
|
|
|
|
|
[5]
|
Prevalence and factors associated with reported adverse-events among patients on multi-drug-resistant tuberculosis treatment in two referral hospitals in Uganda
BMC Infectious Diseases,
2023
DOI:10.1186/s12879-023-08085-3
|
|
|
|
|
[6]
|
Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study
Frontiers in Medicine,
2022
DOI:10.3389/fmed.2021.790718
|
|
|
|
|
[7]
|
Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan
Frontiers in Pharmacology,
2022
DOI:10.3389/fphar.2022.876955
|
|
|
|
|
[8]
|
Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study
Frontiers in Pharmacology,
2022
DOI:10.3389/fphar.2022.883483
|
|
|
|
|
[9]
|
ANTITUBERCULOSIS DRUG ALLERGY IN PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS
AVICENNA BULLETIN,
2021
DOI:10.25005/2074-0581-2021-23-2-242-250
|
|
|
|
|
[10]
|
Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study
BMC Infectious Diseases,
2019
DOI:10.1186/s12879-019-3919-1
|
|
|
|
|
[11]
|
Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study
Tuberculosis Research and Treatment,
2019
DOI:10.1155/2019/9429213
|
|
|
|
|
[12]
|
Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study
BMC Pharmacology and Toxicology,
2019
DOI:10.1186/s40360-019-0313-y
|
|
|
|